Skip to main content
An official website of the United States government

Symptom Science Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer NOT-CA-22-085 09/08/2025
Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases NOT-DA-22-048 09/08/2025
Notice of Correction to PAR-25-104, Cancer Prevention and Control Clinical Trials Planning Grant Program NOT-CA-25-023 (R34 Clinical Trials Optional) R34 10/26/2025 Goli Samimi, Ph.D., M.P.H.
Cancer Prevention and Control Clinical Trials Grant Program PAR-25-167 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/08/2027 Goli Samimi, Ph.D., M.P.H.
Cancer Prevention and Control Clinical Trials Grant Program PAR-25-167 (R01 Clinical Trial Required) R01 Clinical Trial Required 01/08/2027 Goli Samimi, Ph.D., M.P.H.
HEAL Initiative: Studies to Enable Analgesic Discovery RFA-NS-25-023 (R61/R33 - Clinical Trial Not Allowed) R61, R33 Clinical Trial Not Allowed 01/16/2027 Rachel Altshuler, Ph.D.
NIH Support for Conferences and Scientific Meetings PA-25-080 (Parent R13 Clinical Trial Not Allowed) R13 Clinical Trial Not Allowed 09/08/2027 Asad Umar, D.V.M., Ph.D.
Cancer Prevention and Control Clinical Trials Planning Grant Program PAR-25-104 (R34 Clinical Trials Optional) R34 10/26/2027 Goli Samimi, Ph.D., M.P.H.
Cancer Prevention and Control Clinical Trials Planning Grant Program PAR-25-103 (U34 Clinical Trials Optional) U34 10/26/2027 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies PAR-25-145 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 01/08/2028 Rachel Altshuler, Ph.D.